OBI Pharma Inc (台灣浩鼎) shares yesterday fell by more than 4 percent, worse than the 0.95 percent decline on the over-the-counter market, as investors reacted negatively to new allegations about a conflict of interest in the company’s shareholding.
The stock closed at NT$415.50 on the Taipei Exchange, down from the previous day’s NT$433. Since the beginning of this year, the drug developer’s shares have dropped 36.56 percent, while the TPEX has increased 1.48 percent over the same period.
The Chinese-language Next Magazine yesterday reported that the daughter of Academia Sinica President Wong Chi-huey (翁啟惠) bought about 3 million shares of OBI Pharma in 2012.
The report said that Wong Yu-shioh (翁郁琇) bought the OBI shares at a relatively low price of NT$31 per share, potentially allowing her to reap billions of New Taiwan dollars in profit.
Academia Sinica, the nation’s leading research academy, works in close collaboration with OBI Pharma. When the company last month released discouraging results on the second and third-phase clinical trials of a new breast cancer drug, OBI-822, Wong Chi-huey voiced his support for the drug, saying that the flawed design of the clinical trial was to blame for the failure.
As a close collaborator of the company and a government official, Wong Chi-huey’s positive comments about OBI-822 have raised eyebrows.
At the legislature’s Finance Committee meeting yesterday, Chinese Nationalist Party (KMT) Legislator-at-large William Tseng (曾銘宗) raised the issue and demanded that the financial regulator take action on the matter.
“If his daughter is confirmed to have received the 3 million shares from Ruentex Group (潤泰集團), Wong Chi-huey cannot just walk away,” Tseng said, referring to the magazine report.
Ruentex Group is one of OBI Pharma’s major shareholders.
According to the latest data from the Taiwan Stock Exchange, as of June 24, 2014, Wong Yu-shioh held 1.93 million shares, or 1.29 percent, of OBI Pharma stock.
Earlier this month, Tseng urged the Financial Supervisory Commission to determine if Wong Chi-huey had violated the Securities and Exchange Act (證券交易法) by speaking on behalf of OBI Pharma.
Financial Supervisory Commission Chairwoman Jennifer Wang (王儷玲) told the committee meeting that based on an internal investigation, the commission had found that there were concerns over the matter.
“We have forwarded all related materials in our hands to prosecutors for further investigation,” Wang said.
OBI Pharma chairman Michael Chang (張念慈) later in the day issued a statement saying that information about all major shareholders were already made public before the company started trading on the smaller Emerging Stock Market in 2012.
In the statement, Chang said that Wong Yu-shioh was one of the major shareholders of US-based Optimer Pharmaceuticals Inc, the parent company of OBI Pharma at the time, and she bought the shares before its Emerging Stock Market debut in 2012.
Chang also voiced his support for Wong Chi-huey, saying that previous remarks made by the scientist should not be taken as signs of stock market manipulation.
Chinese-language monthly Wealth Magazine executive director Hsieh Chin-ho (謝金河) yesterday questioned Wong Chi-huey’s role in the company.
“Some people might find president Wong being so positive [on the company] is likely due to the massive interests behind,” Hsieh wrote on Facebook.
Media personality Clara Chou (周玉蔻) said that the ongoing affair is destroying Wong’s reputation and would further harm the prospects of Taiwan’s biotech industry.
MediaTek Inc (聯發科) yesterday announced it would give incentive bonuses totaling NT$1.7 billion (US$59.7 million) to its employees and those at the firm’s major subsidiaries, after the smartphone chip supplier’s revenue hit US$10 billion last year. This is the biggest incentive bonus the Hsinchu-based handset chip designer has ever distributed in its 23-year history. About 17,000 full-time employees of MediaTek and five of its subsidiaries, including Richtek Technology Corp (立錡科技) and Airoha Technology Corp (絡達科技), would receive a “red envelope” of NT$100,000 each, the company said. “Surpassing US$10 billion is just the beginning. We will continue to [grow] on this basis,” MediaTek
TO SPUR REVENUE: The contract chipmaker expects its profit to grow 15 percent this year, outpacing the foundry industry’s projected advance of about 10 percent Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday raised its projected capital spending for this year by 62 percent, a new high, in an attempt to satisfy customer demand for advanced technologies in the production of central processing units, high-performance-computing (HPC) devices and 5G applications. After investing US$17.24 billion last year, TSMC this year plans to spend US$25 billion to US$28 billion on manufacturing equipment and new facilities, including a fab in the US. About 80 percent of the budget would be allocated for developing advanced technologies including 3, 5 and 7-nanometer technologies, the company said. The larger-than-expected capital spending prompted speculation
CHINESE TIE-UP: The firm said its services with Zhejiang Geely would be related to vehicles, parts, intelligent drive systems and automotive ecosystem platforms Apple Inc’s local manufacturing partner Hon Hai Precision Industry Co (鴻海精密), known as Foxconn Technology Group (富士康科技集團) outside of Taiwan, is setting up a vehicle venture, strengthening its automotive capabilities at a time when technology companies, including its California ally, are looking to expand in automaking. Hon Hai is joining forces with Chinese automaker Zhejiang Geely Holding Group Co (浙江吉利控股集團) to provide production and consulting services to global automotive enterprises, the companies said in a statement yesterday. The production and consulting services are related to whole vehicles, parts, intelligent drive systems and automotive ecosystem platforms, Hon Hai said in a filing with
RECORD BUDGET: TSMC does plan to raise its proposed capital expenditure a lot, and could benefit if Intel outsources more of its production to foundries, analysts said Intel Corp’s earnings conference call on Thursday is expected to clarify the US semiconductor giant’s outsourcing production plans, which would be crucial regarding Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) performance, analysts said. “TSMC stands to benefit if Intel outsources more of its fabrication to foundries,” SinoPac Securities Investment Service Corp (永豐投顧) analysts said in a note on Friday. Yuanta Securities Investment Consulting Co (元大投顧) was more cautious, saying that Intel’s contribution initially would be limited, but its outsourcing plans would still highlight TSMC’s leadership in technology, it added. “Intel will continue to manufacture server or high-end central processing units [CPUs], which have higher
RSS